RE:Is that our way?Yes. A 1 for 11 share exchange ratio, followed by a 1 for 3 or 4 consolidation post merger has been proposed so effectively a 1 for 33 to 1 for 44 share rollback.
From CZO, a desrisked base business to support R&D to a merger with AEZS a cash burning biotech so management of both companies can sustain their salaries by raising funds to continue the grift. Absolutely no synergies or business sense for this takeover of CZO at a liquidation valuation.
OATS, communication among shareholders is the greatest threat to Gilles.
.